Skip to content
drillr.ai
Sign up

PFSA

Profusa, Inc. Common Stock

NASDAQ · Healthcare · Medical - Equipment & Services · US

$2.72
+3.82%
Ask drillr

  • Sep 1, 2026, 12:17 UTC

    Profusa, Inc. issued a senior secured convertible promissory note to Ascent Partners Fund LLC, with a principal amount of $329,670.33 and a purchase price of $300,000, bearing 7% annual interest and convertible into common stock at $4.28 per share.

  • Aug 31, 2026, 12:56 UTC

    Profusa, Inc. regained compliance with Nasdaq Rule 5550(a)(4) regarding minimum public float, as determined by Nasdaq on August 21, 2026.

  • Aug 21, 2026, 00:00 UTC

    Profusa, Inc. amended its securities purchase agreement with Ascent Partners Fund LLC, adding a new note form and amending the exercise price of a previously issued warrant to $1.07 per share.

  • Aug 20, 2026, 14:49 UTC

    Profusa reported progress toward satisfying conditions for its potential acquisition of G3 Vision Labs, but has not yet exercised its option to acquire the commercial-stage diagnostics business.

    Source:

  • Aug 20, 2026, 12:30 UTC

    Debt and liability holders executed $10.7 million of Series A Convertible Exchange Agreements with Profusa, of which $4.57 million was converted into Series A Convertible Preferred Stock.

    Source:

  • Aug 20, 2026, 00:00 UTC

    Profusa, Inc. reported a net loss of $8.8 million for Q2 2026, with cash on hand of $719,000 as of June 30, 2026.

    Source:

  • Aug 13, 2026, 11:00 UTC

    Profusa, Inc. announced a 1-for-4 reverse stock split of its common stock, effective August 17, 2026, with trading on Nasdaq under ticker PFSA and a new CUSIP number.

    Source:

  • Jul 31, 2026, 00:00 UTC

    Profusa, Inc. completed a private placement of 201,120 shares of common stock and 52,903.566 shares of Series A Non-Voting Convertible Preferred Stock (each convertible into 1,000 common shares upon stockholder approval) to accredited investors, exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

  • Jul 27, 2026, 10:00 UTC

    Profusa signed a non-binding term sheet to acquire a commercial-stage diagnostics company.

    Source:

  • Jul 27, 2026, 00:00 UTC

    Ben Hwang resigned as Director of the Board of Profusa, Inc., effective July 26, 2026.

  • Jul 27, 2026, 00:00 UTC

    Jack Stover was appointed Executive Chairman of the Board and Chief Executive Officer of Profusa, Inc., effective July 21, 2026.

    Source:

  • Jul 2, 2026, 15:00 UTC

    Profusa announced a 1-for-25 reverse stock split of its common stock, effective July 7, 2026.

    Source: